Association between radioiodine therapy for Graves' hyperthyroidism and thyroid-associated ophthalmopathy

International Ophthalmology

Volumn 30, Issue 4, 2010, Pages 397-405

  El Kaissi, Samer ^a   Bowden, Joanne ^a   Henry, Margaret J ^a   Yeo, Myra ^a   Champion, Bernard L ^b   Brotchie, Peter ^c   Nicholson, Geoffrey C ^a   Wall, Jack R ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GEELONG HOSPITAL   (Australia)

Author keywords

Carbimazole; Graves' disease; Magnetic resonance imaging; Ophthalmopathy; Radioactive iodine

Indexed keywords

ATENOLOL; CARBIMAZOLE; RADIOACTIVE IODINE; THYROTROPIN; ANTITHYROID AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; FEMALE; GRAVES DISEASE; HUMAN; MALE; MUSCLE MASS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; THERAPY EFFECT; BLOOD; CHEMICALLY INDUCED; MIDDLE AGED; ORBIT; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; THYROID FUNCTION TEST; TIME;

ADULT; ANTITHYROID AGENTS; CARBIMAZOLE; DISEASE PROGRESSION; FEMALE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCULOMOTOR MUSCLES; ORBIT; PROSPECTIVE STUDIES; THYROID FUNCTION TESTS; THYROTROPIN; TIME FACTORS;

EID: 77956186200     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-010-9368-x     Document Type: Article

References (26)

1. Burch HB, Wartofsky L (1993) Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14:747-793
2. Tallstedt L, Lundell G, Torring O et al (1992) Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326:1733-1738
3. Bartalena L, Marcocci C, Bogazzi F et al (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73-78 (Pubitemid 28042269)
4. Gorman CA, Offord KP (1998) Therapy for hyperthyroidism and Graves' ophthalmopathy. N Engl J Med 338:1546-1547
5. Werner SC, Coelho B, Quimby EH (1957) Ten year results of I-131 therapy of hyperthyroidism. Bull N Y Acad Med 33:783-806
6. Calissendorff BM, Soderstrom M, Alveryd A (1986) Ophthalmopathy and hyperthyroidism. A comparison between patients receiving different antithyroid treatments. Acta Ophthalmol (Copenh) 64:698-703
7. Manso PG, Furlanetto RP, Wolosker AM, Paiva ER, de Abreu MT, Maciel RM (1998) Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism. Thyroid 8:49-52
8. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 90:5321-5323
9. Sridama V, DeGroot LJ (1989) Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 87: 70-73
10. Feldt-Rasmussen U, Bech K, Date J, Petersen PH, Johansen K (1982) A prospective study of the differential changes in serum thyroglobulin and its autoantibodies during propylthiouracil or radioiodine therapy of patients with Graves' disease. Acta Endocrinol (Copenh) 99: 379-385
11. Bartalena L, Pinchera A, Marcocci C (2000) Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21:168-199
12. Pinchera A, Wiersinga W, Glinoer D et al (1992) Classification of eye changes of Graves' disease. Thyroid 2: 235-236
13. Prummel MF, Bakker A, Wiersinga WM et al (2003) Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol 148:491-495
14. Wiersinga WM, Perros P, Kahaly GJ et al (2006) Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155:387-389
15. Kung AW, Yau CC, Cheng A (1994) The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 79:542-546
16. Villadolid MC, Yokoyama N, Izumi M et al (1995) Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 80:2830-2833
17. Barth A, Probst P, Burgi H (1991) Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine. J Endocrinol Invest 14:209-212
18. Bartalena L, Marcocci C, Tanda ML et al (1998) Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 129:632-635
19. Karlsson FA, Dahlberg PA, Jansson R, Westermark K, Enoksson P (1989) Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol (Copenh) 121(Suppl 2):132-141
20. Kriss JP, Pleshakov V, Rosenblum AL, Holderness M, Sharp G, Utiger R (1967) Studies on the pathogenesis of the ophthalmopathy of Graves' disease. J Clin Endocrinol Metab 27:582-593
21. DeGroot LJ, Mangklabruks A, McCormick M (1990) Comparison of RA 131I treatment protocols for Graves' disease. J Endocrinol Invest 13:111-118
22. Tallstedt L, Lundell G, Blomgren H, Bring J (1994) Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494-497
23. Gorman CA (1995) Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 80:340-342
24. Gorman CA (1998) The measurement of change in Graves' ophthalmopathy. Thyroid 8:539-543
25. Wiersinga WM (1998) Preventing Graves' ophthalmopathy. N Engl J Med 338:121-122
26. Bonnema SJ, Bartalena L, Toft AD, Hegedus L (2002) Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol 147:1-11